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Elevated thymidine phosphorylase has been shown to correlate with increased angiogenesis and poor prognosis in many cancers
including transitional cell carcinoma of the bladder. In vitro studies have demonstrated that thymidine phosphorylase activity causes
cellular oxidative stress and increases secretion of vascular endothelial growth factor. In this study, we show that thymidine
phosphorylase activity also augments levels of the hypoxia-inducible factor-1a during in vitro hypoxia, and that thymidine
phosphorylase activity and hypoxia act in concert to increase vascular endothelial growth factor (VEGF) secretion. We also
demonstrate that thymidine phosphorylase overexpression confers tumorigenicity on an orthotopically implanted transitional cell
carcinoma cell line. Administration of the antioxidant N-acetylcysteine together with a blocking anti-VEGF antibody abrogates the
increase in tumorigenicity. Our results support the increased efficacy of combination approaches to antiangiogenic therapy.
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While bladder cancer was responsible for around 46000 deaths in
Europe and North America in 2000, there were 151000 new
diagnoses that year. This difference between incidence and death
rate is due to the heterogeneous clinical behaviour of the
transitional cell carcinomas (TCCs) that account for almost all
bladder tumours in the developed world. 70–80% of TCCs present
as superficial, papillary tumours (stages Ta and T1). With
treatment, 5-year survival in these patients should approach
90–95%, with the majority of patients either cured, or dying with
(not from) their bladder cancer. Unfortunately, for the 20–30%
of tumours that present at stages T2–T4, and the minority of
superficial tumours that progress despite treatment, 5-year
survival rates are much lower. The prognosis of patients with
muscle-invasive carcinoma is poor for two reasons. Firstly,
invasion promotes local, lymphatic and haematogeneous dissemi-
nation. In addition, invasive disease necessitates radical surgery
or radiotherapy, with the morbidity these entail. There is therefore
a need to identify the mechanisms that increase tumorigenicity in
TCC.
The ‘angiogenic enzyme’ thymidine phosphorylase (TP) is
commonly upregulated in many solid tumours including TCC
(O’Brien et al, 1996), and overexpression has been shown to
correlate with increased tumour invasion (O’Brien et al, 1996;
Sawase et al, 1998) and poor prognosis (Arima et al, 2000) in
bladder carcinoma. While TP has been known to be angiogenic for
many years (Ishikawa et al, 1989), the precise mechanism has
remained elusive. We have previously shown that TP activity
induces oxidative stress in a TCC cell line, possibly via the
production of strongly reducing sugars that generate oxygen free
radicals during the early steps of protein glycation (Brown et al,
2000). One consequence of TP activity in this cell line is increased
expression of the angiogenic factor vascular endothelial growth
factor (VEGF) (Brown et al, 2000). Increased VEGF expression has
been shown to correlate with recurrence and progression in
bladder tumours (Crew et al, 1997). Transcription of the VEGF
gene is known to be driven by the hypoxia-inducible factor HIF-1a,
and recent evidence has suggested that cellular HIF-1a levels are
raised not only by hypoxia but are also increased in the presence
of reactive oxygen species (ROS) (Page et al, 2002; Gao et al, 2002).
We have therefore conducted in vitro experiments to determine
whether hypoxia and TP activity can cooperatively increase VEGF
production by a TCC cell line.
As noted above, elevated TP has been shown to correlate with
aggressive TCC behaviour in clinical studies. It is not, however,
possible to use observational clinical data to prove that TP activity
is causal. Thymidine phosphorylase levels might be increased
secondary to the microenvironmental changes that accompany
tumour growth and invasion. For instance, cellular TP levels are
known to be highly responsive to the local cytokine milieu (Goto
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set al, 2001). To demonstrate causality, we have compared the in
vivo behaviour of two TCC cell lines, one transfected with the TP
gene (RT112-TP), the other an empty vector control (RT112-EV).
Differences in the tumorigenicity of TCC cell lines are best
demonstrated by orthotopic implantation, rather than xenograft-
ing into the mouse flank (Kerbel et al, 1991). We have therefore
implanted RT112-TP and RT112-EV into the bladder walls of
athymic rats, via laparotomy. Finally, we aimed to determine
whether ROS and VEGF might increase the tumorigenicity of TP-
overexpressing TCC in vivo. If this is the case, then therapies that
diminish tumour cell oxidative stress and counter VEGF activity
should reduce the tumorigenicity of TP-overexpressing carcino-
mas. To test this theory in vivo, we have treated rats with the
antioxidant N-acetyl cysteine (NAC) and an anti-VEGF mono-
clonal antibody, to determine the effect of these interventions
upon the tumorigenicity of RT112-TP.
MATERIALS AND METHODS
Materials
The cell lines RT112-EV and RT112-TP have previously been
described (Brown et al, 2000). VG76e is an anti-human VEGF
mouse monoclonal antibody that has previously been shown to
block VEGF activity, both by its inhibition of VEGF-dependent
growth stimulation of human umbilical vein endothelial cells in
vitro, and its abrogation of angiogenesis in the primate corpus
luteum in vivo (Fraser et al, 2000).
Cell culture for in vitro experiments
RT112-EV and RT112-TP cells were cultured in DMEM containing
25mM glucose and 10% fetal calf serum. At 16h prior to the start of
the experiment, cells were transferred to DMEM containing 5.5mM
glucose, 0.01% bovine serum albumin, 45mgml
 1 streptomycin,
45mgml
 1 penicillin, and 40mgml
 1 kanamycin (Life Technologies,
Paisley, UK).
Immunoblotting
RT112-EV and RT112-TP cells were cultured to around 80%
confluence. Cells were then fed with control medium, or medium
containing 500mM thymidine, for 10h. After this, the cells were
placed in normoxia or hypoxia (0.1% oxygen) for a further 6h. At
harvest, the cells were lysed in sodium phosphate/SDS buffer (pH
7.2) containing ‘Complete, EDTA-free’ protease inhibitors (Roche
Diagnostics, Lewes, UK). Lysates were centrifuged to remove
particulates, and the protein concentration determined using the
bicinchonic acid protein assay (Pierce & Warriner, Chester, UK).
Protein lysate (50mg) was separated by electrophoresis on a 12%
acrylamide gel and transferred to an Immobilon-P membrane
(Millipore, Watford, UK). After blocking, the membrane was
probed overnight at 41C with anti-HIF-1a mouse monoclonal
antibody NB100-123 diluted 1:750 (Novus Biologicals, Littleton,
USA). Goat anti-mouse horseradish peroxidase-conjugated
secondary antibody (Dako, Ely, UK) was used at 500mgl
 1, and
HIF-1a visualised using the Renaissance enhanced luminol system
(New England Nuclear, Hounslow, UK) and Hyperfilm (Amersham
Pharmacia Biotech, Little Chalfont, UK). The membrane was then
stripped by two 5-min rinses in 200mM sodium hydroxide,
followed by two 5-min rinses in distilled water, reblocked and
immunoblotted for haem oxygenase-1 (HO-1), using the anti HO-1
mouse monoclonal antibody OSA-110 at 0.6mgml
 1 (Stressgen,
Victoria, Canada). After visualisation of the HO-1 bands, the
membrane was again stripped, and probed with the anti b-tubulin
mouse monoclonal antibody T4026 at 0.26mgml
 1 (Sigma-Aldrich,
Poole, UK).
ELISA experiments
RT112-TP cells were seeded into six-well plates at 1 10
5
cellswell
 1 and cultured for 24h. Triplicate data were obtained
by allocating three wells of RT112-TP to each treatment. The
growth medium was replaced with serum-free medium containing
5.5mM glucose, and the cells incubated for an additional 24h. The
cells were then treated with 0 or 200mM thymidine for 6h, and then
transferred to 21 or 0.1% oxygen for the remaining 10h of the
experiment. Some wells were treated with 50mM of the TP inhibitor
5-chloro-6-[1-(2-iminopyrrolidinyl)methyl] uracil hydrochloride
(TPI), a gift from Dr M Fukushima, Taiho Pharmaceutical Co.
Ltd, Saitama, Japan. Conditioned medium was collected, centri-
fuged to remove particulates, and frozen at  801C for future
analysis by ELISA. Concurrently, the cells in each well were
released by exposure to trypsin, and their number determined by
Coulter Counter. The VEGF concentration in the conditioned
medium was then determined by ELISA (R&D Systems, Abingdon,
UK). These results were then divided by the number of cells in
the corresponding well, to obtain a value in picograms of VEGF
produced per million cells per 16h. The data were examined for
significance by Kruskall–Wallis analysis.
Orthotopic implantation of RT112-EV and RT112-TP cells
into the immunodeficient rat bladder
Nude 3-week-old immunodeficient rats were purchased from
Harlan UK Ltd, (Bicester, UK). The cell lines RT112-EV and
RT112-TP were prepared by retroviral transfection of the RT112
cell line (Brown et al, 2000). Orthotopic implantation of RT112-TP
and RT112-EV into the nude rat bladder wall was performed
essentially as described by Oshinsky et al (1995). Briefly, following
anaesthesia the bladder was exposed via a 5mm midline
abdominal incision. In all animals, 5 10
6cells in a 100ml volume
were injected via a 27 gauge needle directly into the bladder wall
and the abdomen washed and sutured. Treatment schedules
involved administration of NAC (0.1gml
 1) ad libitum in the
drinking water and/or a VG76e (500mg) bolus intraperitoneally
(i.p.) twice weekly. Rats were killed 6 weeks after implantation and
the bladders examined. Animal procedures were performed in
accordance with the UK Home Office licence number 70/4949.
Each experiment employed the minimum number of rats needed
to obtain statistically meaningful results. Tumour take data were
analysed by Fisher’s exact test.
Immunohistochemistry
Immunohistochemistry was performed using the standard ABC-
HRP protocol. Paraffin-embedded sections were dewaxed, rehy-
drated and then microwaved twice in 10mM sodium citrate buffer
(pH 6.0). Endogenous peroxidase activity was blocked with 3%
hydrogen peroxide (5min at room temperature). After blocking
with 1:20 fetal calf serum in PBS, the sections were incubated with
primary antibody. Anti-HO-1 (Calbiochem, Nottingham, UK) and
anti-4-hydroxy-2-nonenal (Autogen Bioclear, Calne, UK) antisera
were both rabbit anti-mouse. The Vector ABC-Elite kit (Vector
Laboratories, Peterborough, UK) was used, and peroxidase activity
was visualised with metal-enhanced diaminobenzidine (Perbio,
Cramlington, UK).
RESULTS
Thymidine phosphorylase activity augments the hypoxic
induction of HIF-1a in RT112-TP
RT112-EV and RT112-TP cells were exposed to thymidine and
hypoxia, either alone or in combination, and levels of HIF-1a
protein were analysed by immunoblotting. In addition, the levels
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sof HO-1, a marker of oxidative stress, and the loading control
b-tubulin were also measured. This was performed by repeat
immunoblotting of the same membrane (Figure 1). As predicted by
previous in vitro studies (Brown et al, 2000), HO-1 levels were
increased in RT112-TP treated with thymidine, suggesting that
these cells are under oxidative stress due to TP activity. An
additional, novel, finding was that coexposure of the RT112-TP
cells to thymidine and hypoxia gave greater induction of HIF-1a
protein than did exposure to hypoxia alone. Exposure to
thymidine alone did not increase levels of HIF-1a. Treatment of
RT112-EV with thymidine did not induce HO-1, and the hypoxic
induction of HIF-1a was not augmented by thymidine treatment of
RT112-EV.
Hypoxia and thymidine additively increase the secretion of
VEGF by RT112-TP
Figure 2 shows VEGF production by the cell line RT112-TP in
vitro, following exposure to hypoxia and/or thymidine. Both
hypoxia alone and thymidine alone induce VEGF. A combination
of hypoxia and thymidine gave significantly higher VEGF levels
than treatment with either agent alone. We have also demonstrated
that TP activity is the cause of increased VEGF production in
thymidine-treated RT112-TP, both in normoxic and hypoxic
conditions. 50mM of ‘TPI’, a specific inhibitor of TP activity
(Matsushita et al, 1999), significantly attenuated the increase in
VEGF secretion seen with thymidine treatment of RT112-TP. TPI
had no effect upon baseline levels of VEGF production, however.
0 M thymidine  500 M thymidine 
21% O2 0.1% O2 21% O2 0.1% O2
HIF-1
-Tubulin
HO-1
RT112-EV
0 M thymidine  500 M thymidine 
21% O2 0.1% O2 21% O2 0.1% O2
RT112-TP
HIF-1
-Tubulin
HO-1
A
B
Figure 1 Treatment of RT112-TP with thymidine further augments HIF-1a levels under hypoxia. Duplicate dishes of RT112-TP and RT112-EV were
exposed to thymidine and/or hypoxia. Immunoblotting for the hypoxia-inducible factor HIF-1a was then undertaken. In addition, levels of the marker
of oxidative stress HO-1, and the loading control b-tubulin, were also assessed. As with previous in vitro studies (Brown et al, 2000), HO-1 levels were
increased in RT112-TP treated with thymidine, but were not raised in thymidine-treated RT112-EV, suggesting that TP activity causes oxidative stress. The
hypoxic induction of HIF-1a was greater in the plates where RT112-TP had been exposed to thymidine, implying a cooperative induction of HIF-1a by
hypoxia and TP activity. In contrast, thymidine treatment of RT112-EV has no effect upon the hypoxic induction of HIF-1a in this control cell line.
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Figure 2 RT112-TP treated with thymidine and hypoxia secrete
significantly more VEGF than cells receiving either treatment alone.
Triplicate wells of RT112-TP were exposed to one of four treatments
(0mM thymidineþ21% oxygen; 200mM thymidineþ21% oxygen; 0mM
thymidineþ0.1% oxygen; 200mM thymidineþ0.1% oxygen). Mean VEGF
production (þone standard error), expressed as picogram VEGF/million
cells/16h of culture is shown. As expected, both thymidine and hypoxia
alone increased VEGF secretion. However, RT112-TP treated with both
thymidine and hypoxia produced significantly more VEGF than those
treated with thymidine alone (P¼0.0495, Kruskall–Wallis analysis), and
also secreted significantly more VEGF than RT112-TP exposed to hypoxia
alone (P¼0.0495, Kruskall–Wallis analysis). (*¼significant difference by
Kruskall–Wallis analysis).
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sThese findings applied to RT112-TP in normoxia (Figure 3A), and
also to RT112-TP in hypoxic conditions (Figure 3B).
Thymidine phosphorylase overexpressing RT112 human
bladder carcinoma cells are more tumorigenic than control
cells when implanted into the bladders of athymic rats
The two transfectant cell lines derived from the human TCC cell
line RT112 were directly implanted into the bladder walls of
athymic rats. Implantation of the empty vector control cell line
RT112-EV led to the establishment of only one tumour in 14
implants. The TP-transfectant cell line RT112-TP, however, gave
tumours in six out of 12 rats. Fisher’s exact test was used to
confirm that RT112-TP is significantly more tumorigenic than
RT112-EV in this orthotopic xenograft model (P¼0.03).
Combination therapy with an antioxidant and an anti-
VEGF antibody decreases the in vivo tumorigenicity of
RT112-TP
It has previously been shown that TP activity correlates with
cellular oxidative stress in vitro (Brown et al, 2000). To confirm the
presence of oxidative stress in orthotopically implanted RT112-TP,
we excised a RT112-TP tumour from the rat bladder and
immunostained it for two known markers of oxidative stress. 4-
Hydroxy-2-nonenal is the major end product of oxidative fatty
acid metabolism and is generated by a free radical chain reaction
mechanism during oxidative stress (Esterbauer et al, 1991), and
4-hydroxy-2-nonenal-modified proteins are markers of oxidative
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Figure 3 Increased VEGF production by thymidine-treated RT112-TP is
due to TP activity in both normoxic and hypoxic conditions. During the
same experiment as shown in Figure 2, triplicate wells of RT112-TP were
also exposed to thymidine in the presence of 50mM TPI, a specific inhibitor
of TP activity (Matsushita et al, 1999), under normoxic (A) and hypoxic (B)
conditions. Mean VEGF production (þone standard error) is expressed as
picogram VEGF/million cells/16h of the culture. The data for the TPI-free
wells are taken from Figure 2. (A) In normoxia, TPI abolished the
thymidine-dependent increase in VEGF secretion by RT112-TP
(P¼0.0495, Kruskall–Wallis analysis), but had no effect upon baseline
VEGF production (P¼0.51, Kruskall–Wallis analysis). (B) In hypoxia, TPI
abolished the thymidine-dependent increase in VEGF secretion by RT112-
TP (P¼0.0495, Kruskall–Wallis analysis), but had no effect upon baseline
VEGF production (P¼0.51, Kruskall–Wallis analysis). These results confirm
that TP activity is responsible for the increased VEGF production observed
in thymidine-treated RT112-TP. (NS¼no significant difference by
Kruskall–Wallis analysis. *¼significant difference by Kruskall–Wallis
analysis).
Figure 4 Immunohistochemical staining of the oxidative stress markers
haem oxygenase-1 (HO-1) and 4-hydroxy-2-nonenal in RT112-TP
tumours. The top panel is a low-power view with haematoxylin stain.
The arrows indicate the sections stained for HO-1 (middle panel) and
4-hydroxy-2-nonenal (lower panel). The ex vivo RT112-TP tumour stained
positive for both HO-1 and 4-hydroxy-2-nonenal. All normal tissues
examined, including bladder, were negative for these markers (see Results).
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sstress (Temma et al, 2004). Oxidative stress also induces haem
oxygenase, and this can be used as a marker for stressed cells
(Smith et al, 1994). The ex vivo tumour stained positive for both
markers (Figure 4). Immunostaining was negative on the normal
bladder, lung, liver and kidney. It has also been demonstrated that
TP activity increases in vitro production of VEGF (Brown et al,
2000). Oxidative stress and VEGF activity may therefore play key
roles in the increased in vivo tumorigenicity of TP-overexpressing
carcinomas, and represent potential therapeutic targets. To
examine their relative contribution to tumour take, we adminis-
tered the antioxidant NAC and/or the anti-VEGF monoclonal
antibody VG76e to 30 further rats carrying orthotopic implants
of the TP overexpressing TCC cell line RT112-TP. Eight received
no treatment, seven were given NAC (0.1gml
 1 ad libitum in
drinking water), eight were administered VG76e (500mg i.p. bolus
dose twice weekly), and seven were subject to both interventions.
After 6 weeks, four out of eight of the control group had developed
a bladder tumour, but only two out of seven of the NAC group and
two out of eight of the VG76e group showed evidence of tumour
take. Of the seven rats receiving both treatments, none developed
a tumour. The decreased tumour take in the rats receiving a single
therapy was not statistically significant. The absence of tumours in
the group given dual therapy was of borderline significance when
eight rats from the second experiment alone were included in the
control group (P¼0.08, Fisher’s exact test). It is valid, however, to
expand the control group analysis to include rats from the first
experiment, giving a control group with 10 out of 20 rats
developing tumours. This is because the experiments were carried
out under identical conditions, and the two control groups gave
identical results. Analysis of this data using Fisher’s exact test
confirms that the tumorigenicity of RT112-TP in vivo is
significantly decreased by coadministration of NAC and VG76e
(P¼0.03).
DISCUSSION
The initial part of this study furthers our understanding of the
mechanisms that link TP activity and tumour behaviour. We show
that in the presence of hypoxia, TP activity further increases the
induction of cellular HIF-1a. In contrast, others have shown that
the enzymatic product of thymidine phosphorylase’s action on
thymidine, 2-deoxy-D-ribose, attenuates the hypoxic induction of
HIF-1a in the leukaemic cell line HL-60 (Ikeda et al, 2002). It is
therefore possible that different tumour cell lines may demonstrate
considerable variation when studying the effects of TP activity
upon HIF-1a induction. It has been known for several years that
2-deoxy-D-ribose reduces hypoxia-induced apoptosis in the cell
lines KB-3-1 and HL-60 (Kitazono et al, 1998) (Ikeda et al, 2002).
It would therefore be of future interest to determine whether TP
activity promotes or represses hypoxia-induced apoptosis in our
bladder carcinoma cell line. Heterogeneity of response when
comparing cell lines may be further increased by the fact that HIF-
1a is proapoptotic in some cell lines, but antiapoptotic in others
(Greijer and van der Waal, 2004).
We have also shown that in the TP-transfectant bladder
carcinoma cell line RT112-TP expression of the angiogenic factor
VEGF was enhanced by the presence of both thymidine and
hypoxia in vitro. These results confirm those of our previous
study, and are of interest in the light of the findings of Nakajima
et al (2004), who demonstrated that 2-deoxy-L-ribose, the
stereoisomer of TP’s product, suppressed the hypoxic expression
of VEGF by the carcinoma cell line KB-3-1. Our results suggest that
hypoxic stress, and oxidative stress caused by TP activity, may
cooperatively stabilise HIF-1a and increase VEGF production in
our TCC cell line. Initially, it appears counter-intuitive that a cell
could experience both hypoxic and oxidative stress at the same
time. Such concurrence is possible, however, because ROS exert
their biological effects at extremely low concentrations – levels
even lower than the concentration of molecular oxygen in a
hypoxic environment.
We then demonstrated that TP overexpression significantly
increases the tumorigenicity of bladder carcinoma cells implanted
into the bladders of athymic rats. A large number of clinical
research papers have shown a statistically significant correlation
between TP expression and either tumour invasion or poor
prognosis, but these observational studies cannot prove the
presence of a causal relationship. In addition, the thymidine
phosphorylase inhibitor (TPI) has been shown to reduce both
tumour invasion and distant metastasis of a TP-expressing solid
tumour in a mouse model (Takao et al, 2000). Jones and colleagues
have previously used the ex vivo de-epithelialised rat bladder
model to investigate the effects of TP upon the tumorigenicity of
the RT112 cell line. They found that RT112-TP cells invaded the
stroma of the ex vivo de-epithelialised rat bladder, while RT112-EV
did not (Jones et al, 2002). Our experiments have shown for the
first time that a TP-transfected bladder carcinoma cell line is
significantly more tumorigenic than its empty vector control in
the bladders of living rats. We believe that this strongly suggests
a causal relationship between TP activity and aggressive tumour
behaviour in the bladder.
Finally, we demonstrated that by administering both a mono-
clonal anti-VEGF antibody and the antioxidant NAC to the
experimental animals, we could significantly reduce the tumor-
igenicity of RT112-TP in the nude rat bladder. We chose to
investigate the therapeutic potential of an anti-VEGF monoclonal
antibody because of evidence that VEGF may be an important
mediator acting downstream of TP activity (Brown et al, 2000).
N-acetyl cysteine was employed as our second agent because of
its successful use in three previous studies. Firstly, the in vitro
induction of carcinoma cell HO-1 by TP activity is abolished by
NAC (Brown et al, 2000). The second study used the ex vivo de-
epithelialised rat bladder model, and demonstrated that NAC
reduced invasion of the stroma by a range of TCC cell lines
(Fujiyama et al, 2001). Finally, Albini and colleagues have shown
that NAC reduces tumorigenicity in a variety of animal models.
For example, they have demonstrated that oral NAC inhibits the
growth of a subcutaneously implanted Kaposi’s sarcoma cell line
in a murine model (Albini et al, 2001). Interestingly, they found
VEGF production to be significantly reduced in the Kaposi’s
sarcomas from NAC-treated mice.
Anti-VEGF monoclonal antibodies and NAC are already in
clinical use. The anti-VEGF antibody bevacizumab (Avastin) has
recently completed large-scale phase III trials in advanced
colorectal carcinoma (Kabbinavar et al, 2003) (Hurwitz et al,
2004). NAC (under its trade name ‘Parvolex’) has been the
established first-line treatment of paracetamol overdose for many
years. Both therefore have well-characterised clinical safety
profiles, and may thus merit further investigation as therapeutic
adjuncts in combination treatment of bladder carcinoma.
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